All In Biotech

Drug Trial Radar · NCT00624338

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)

Last checked: Nov 20, 2026Latest source record: Mar 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 461 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

461

Actual

Start

Jan 2008

Primary completion

Apr 2012

Study completion Oct 2012

Sponsor

Lead sponsor
EMD SeronoIndustry
Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Feb 27, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the efficacy and safety of atacicept compared to placebo in preventing new flares in subjects with systemic lupus erythematosus (SLE) and to confirm the optimal dose of atacicept for treatment of subjects with SLE and gain information on the effect of atacicept on markers specific to its mechanism of action (MoA) and their correlation to disease activity/progression. Study medication will be administered through subcutaneous (under the skin) injections, beginning with twice weekly injections for the first 4 weeks, followed by once weekly doses for 48 weeks. Following the last treatment, a safety follow-up period of 24 weeks will be conducted.

Conditions

  • Lupus Erythematosus, Systemic

Interventions

  • Atacicept 75 mgDrug

    75 milligram (mg) atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.

  • Atacicept 150 mgDrug

    150 mg atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.

  • Placebo ComparatorOther

    Placebo matched to atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing a New Flare as Defined by British Isles Lupus Assessment Group (BILAG) Score A or BTime frame: From screening up to Week 52

Locations

113 sites in 29 countries. Site status is shown where the registry gives one.

  • Division of Clinical Immunology and Rheumatology - UAB

    Birmingham, Alabama

  • Stanford University

    Palo Alto, California

  • Research Site

    San Diego, California

  • Inland Rheumatology Clinical Trials Inc

    Upland, California

  • Research Site

    Jacksonville, Florida

  • Research Site

    Boise, Idaho

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • US Local Medical Information

    Rockland, Massachusetts

  • Wayne State University

    Detroit, Michigan

  • Justus J. Fiechtner, MD, MPH

    Lansing, Michigan

  • SUNY Health Science Center at Brooklyn

    Brooklyn, New York

  • Feinstein Institute for Medical Research

    Manhasset, New York

  • Hospital for Special Surgey

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Cincinnati, Ohio

  • University of Cincinnati Medical Center, Division of Immunology

    Cincinnati, Ohio

  • Research Site

    Temple, Texas

  • Virginia Mason Medical Center

    Seattle, Washington

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Córdoba, Argentina

  • Research Site

    Quilmes, Argentina

  • Research Site

    San Juan, Argentina

  • Research Site

    San Miguel de Tucumán, Argentina

  • Research Site

    Cairns, Australia

  • Research Site

    Clayton, Victoria, Australia

  • Research Site

    Sunshine Coast, Queensland, Australia

  • Research Site

    Woodville S.A., Australia

  • Research Site

    Wein, Austria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Osijek, Croatia

  • Research Site

    Rijeka, Croatia

  • Research Site

    Split, Croatia

  • Research Site

    Zagreb, Croatia

  • Research Site

    Prague, Czechia

  • Research Site

    Bordeaux Pessac, France

  • Research Site

    Lille, France

  • Research Site

    Montpelier Cedex, France

  • Research Site

    Paris, France

  • Research Site

    Strasbourg, France

  • Research Site

    Toulouse, France

Showing 40 of 113 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.